Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
45.83
+0.69+1.53%
Filing
Up 1.5% — Filed an 8-K material-event report (2026-08-04) — details in the filing.
Medium confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -0.06 | Insider Own | 44.54% | Shs Outstand | 27.39M | Perf Week | -1.78% |
| Market Cap | 1.26B | Forward P/E | 22.43 | EPS next Y | 2.04 | Insider Trans | -3.48% | Shs Float | 21.05M | Perf Month | 20.54% |
| Enterprise Value | 1.26B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 5.83% | Perf Quarter | 51.96% |
| Income | -2.00M | P/S | 14.60 | EPS this Y | 1532.50% | Inst Trans | - | Short Ratio | 2.98 | Perf Half Y | 202.11% |
| Sales | 86.00M | P/B | 52.31 | EPS next Y | 137.74% | ROA | -1.51% | Short Interest | 1.23M | Perf YTD | 171.02% |
| Book/sh | 0.88 | P/C | 50.21 | EPS next 5Y | 64.43% | ROE | -5.68% | 52W High | 50.18 -8.67% | Perf Year | 224.35% |
| Cash/sh | 0.91 | P/FCF | 82.40 | EPS past 3/5Y | - | ROIC | 3.10% | 52W Low | 13.99 227.59% | Perf 3Y | 1697.25% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 56.18% - | Gross Margin | 54.77% | Volatility | 5.65% 5.81% | Perf 5Y | 750.28% |
| Dividend TTM | - | EV/Sales | 14.66 | EPS Y/Y TTM | 60.00% | Oper. Margin | 2.35% | ATR (14) | 2.34 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.88 | Sales Y/Y TTM | 120.51% | Profit Margin | -1.70% | RSI (14) | 63.26 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.21 | EPS Q/Q | -28.57% | SMA20 | 8.98% | Beta | 0.85 | Target Price | 59.67 |
| Payout | 0.00% | Debt/Eq | 1.19 | Sales Q/Q | 41.18% | SMA50 | 25.92% | Rel Volume | 0.74 | Prev Close | 45.14 |
| Employees | 44 | LT Debt/Eq | 0.85 | Earnings | Aug 13 | SMA200 | 91.63% | Avg Volume | 462.97K | Price | 45.83 |
| IPO Date | Nov 14, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -55.88% 8.76% | Net Debt/EBITDA | -1.36 | Volume | 341,768 | Change | 1.53% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-28-26 | Reiterated | Craig-Hallum | Buy | $15 → $62 |
| Jul-16-26 | Initiated | Canaccord | Buy | $60 |
| May-15-26 | Reiterated | HC Wainwright & Co. | Buy | $35 → $57 |
| May-29-25 | Reiterated | HC Wainwright & Co. | Buy | $11 → $35 |
| Oct-28-24 | Reiterated | Craig-Hallum | Buy | $8.00 → $15 |
| Oct-04-24 | Reiterated | HC Wainwright & Co. | Buy | $9.00 → $11 |
| May-06-24 | Initiated | Craig-Hallum | Buy | $8.00 |
| Jul-25-22 | Reiterated | HC Wainwright & Co. | Buy | $9.00 |
Latest News
Aug-03-26
Aug-03-2606:50AM
Jul-29-26
Jul-29-2606:54AM
06:50AM
Jul-20-26
Jul-17-26
Company
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 86 | 80 | 39 | 32 | 21 | 22 | 0 | 1 | 0 | |
| Cost of Goods Sold Incl. D&A | 40 | 37 | 16 | 11 | 7 | 3 | 0 | 0 | 0 | |
| Gross Profit | 48 | 43 | 23 | 21 | 14 | 19 | 0 | 1 | 0 | |
| Selling, General and Administrative Excl. Other | 37 | 36 | 23 | 19 | 19 | 14 | 13 | 8 | 5 | |
| Research and Development | 9 | 8 | 3 | 3 | 4 | 6 | 14 | 12 | 6 | |
| Other Operating Expense | -1 | -1 | 0 | 0 | 0 | 1 | 0 | -1 | -1 | |
| Operating Income | 2 | 0 | -3 | -1 | -8 | -1 | -27 | -19 | -10 | |
| Interest Expense | 2 | 5 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -1 | 0 | 1 | 2 | 0 | 1 | 0 | 0 | -2 | |
| Net Income Before Taxes | -2 | -5 | -4 | -1 | -9 | -2 | -28 | -18 | -13 | |
| Income Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -2 | -5 | -4 | -1 | -9 | -2 | -28 | -18 | -13 | |
| Net Income From Continuing Operations | -2 | -5 | -4 | -1 | -9 | -2 | -28 | -18 | -13 | |
| Net Income | -2 | -5 | -4 | -1 | -9 | -2 | -28 | -18 | -13 | |
| EPS (Recurring) | -0.05 | -0.17 | -0.15 | -0.04 | -0.36 | -0.08 | -1.33 | -1.02 | -1.99 | |
| EPS (Basic, Before Extraordinaries) | -0.05 | -0.17 | -0.15 | -0.04 | -0.36 | -0.08 | -1.33 | -1.02 | -1.99 | |
| EPS (Diluted) | -0.06 | -0.17 | -0.15 | -0.04 | -0.36 | -0.08 | -1.33 | -1.02 | -1.99 | |
| EBITDA | 6 | 4 | -1 | 0 | -7 | -1 | -26 | -18 | -10 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 14.39 | 5.71 | 8.88 | 3.56 | 3.36 | 4.88 | — | 129.60 | — | |
| Gross Margin | 55.81 | 53.75 | 58.97 | 65.63 | 66.67 | 86.36 | — | 100.00 | — | |
| Operating Margin | 2.33 | 0.00 | -7.69 | -3.13 | -38.10 | -4.55 | — | -1,900.00 | — | |
| Net Margin | -2.33 | -6.25 | -10.26 | -3.13 | -42.86 | -9.09 | — | -1,800.00 | — | |
| Shares Outstanding | 27 | 27 | 26 | 26 | 25 | 25 | 21 | 18 | 6 | |
| Market Capitalization | 1,237 | 457 | 346 | 114 | 71 | 107 | 171 | 130 | 37 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner | Jul 14 '26 | Sale | 37.54 | 28,315 | 1,063,033 | 40,000 | Jul 16 |
| BRYNJELSEN SEAN | President & CEO | Jul 14 '26 | Option Exercise | 1.37 | 400,000 | 548,000 | 1,061,194 | Jul 14 |
| BRYNJELSEN SEAN | President & CEO | Jul 12 '26 | Option Exercise | 0.00 | 27,500 | 0 | 861,194 | Jul 14 |
| Krempa David | Chief Business Officer | Jul 12 '26 | Option Exercise | 0.00 | 10,000 | 0 | 37,025 | Jul 13 |
| Opaleye Management Inc. | 10% Owner | Jul 07 '26 | Sale | 38.37 | 26,685 | 1,023,978 | 53,315 | Jul 07 |
| Opaleye Management Inc. | 10% Owner | Jul 06 '26 | Sale | 38.00 | 10,000 | 380,000 | 2,700,000 | Jul 07 |
| Opaleye Management Inc. | 10% Owner | Jul 02 '26 | Sale | 37.39 | 90,000 | 3,364,660 | 60,000 | Jul 07 |
| Adams Jennifer McKie | Director | Jun 17 '26 | Option Exercise | 3.78 | 50,000 | 189,000 | 50,000 | Jun 17 |
| Adams Jennifer McKie | Director | Jun 17 '26 | Sale | 32.48 | 50,000 | 1,623,795 | 0 | Jun 17 |
| BRYNJELSEN SEAN | President & CEO | May 28 '26 | Sale | 31.88 | 120,000 | 3,825,717 | 833,694 | May 29 |
| Krempa David | Chief Business Officer | May 27 '26 | Sale | 31.47 | 19,679 | 619,375 | 25,249 | May 27 |
| Krempa David | Chief Business Officer | May 27 '26 | Option Exercise | 2.18 | 19,679 | 42,879 | 44,928 | May 27 |
| Krempa David | Chief Business Officer | May 26 '26 | Sale | 31.49 | 37,524 | 1,181,732 | 25,249 | May 27 |
| Krempa David | Chief Business Officer | May 26 '26 | Option Exercise | 1.38 | 37,524 | 51,658 | 62,773 | May 27 |
| Krempa David | Chief Business Officer | May 22 '26 | Option Exercise | 3.58 | 30,591 | 109,516 | 68,046 | May 27 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.